July 12, 2014 6:36 AM ET

Biotechnology

Company Overview of Histogenics Corporation

Company Overview

Histogenics Corporation, a biologics company, develops, markets, and commercializes regenerative medicine products for the musculoskeletal segment of the marketplace. The company focuses on regenerative medicine technologies, including cell-based therapies, tissue engineering, and biologics. It offers NeoCart, a cartilage-like tissue implant for treating damage to the articular cartilage of the knee using biological and cell-based therapy; and regenerative medicine platform that combines cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The compan...

830 Winter Street

3rd Floor

Waltham, MA 02451

United States

Founded in 2000

Phone:

781-547-7900

Fax:

781-547-4452

Key Executives for Histogenics Corporation

Chief Executive Officer
Age: 42
Founder and Member of Scientific Advisory Board
Chief Financial Officer
Senior Vice President of Manufacturing
Age: 57
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Histogenics Corporation Key Developments

Histogenics Appoints Kathleen Large, R.N., M.S., to Vice President of Clinical Operations

Histogenics Corporation announced the appointment of Kathleen Large, R.N., M.S., to Vice President of Clinical Operations. Ms. Large will be responsible for management of the company's clinical programs, including the ongoing Phase 3 trial of NeoCart(R), studying the treatment of certain knee cartilage injuries. Prior to joining Histogenics, Ms. Large most recently served as Director, Early Stage Development and Strategic Site Alliances at Millennium Pharmaceuticals.

Histogenics Corporation Appoints Adam Gridley as President and Chief Executive Officer and Member of Board of Director

Histogenics Corporation announced the appointment of Adam Gridley to President and Chief Executive Officer and as a member of the company's Board of Directors. Mr. Gridley brings over 20 years of proven results in the medical device and pharmaceutical industries, with a combination of transactional and public markets experience as well as strong operational leadership and product development expertise. Prior to joining Histogenics, Mr. Gridley most recently served as Senior Vice President, Technical Operations at Merz.

Histogenics Announces Appointment of John H. Johnson to its Board of Directors

Histogenics Corporation announced that John H. Johnson has been appointed to the company's board of directors. Mr. Johnson is currently the chairman, president and chief executive officer of Dendreon Corporation. Prior to joining Dendreon, Mr. Johnson was the chief executive officer and a member of the board of directors of Savient Pharmaceuticals Inc., from January 2011 through January 2012.

Similar Private Companies By Industry

Company Name Region
Parcell Laboratories, Inc. United States
Bioo Scientific Corporation United States
Telovax Corporation United States
Calando Pharmaceuticals, Inc. United States
MMR Life Sciences Group, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 18, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Histogenics Corporation, please visit www.histogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.